Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

mouse model

  • Broad-Spectrum Antiviral Activity of 3′-Deoxy-3′-Fluoroadenosine against Emerging Flaviviruses
    Antiviral Agents
    Broad-Spectrum Antiviral Activity of 3′-Deoxy-3′-Fluoroadenosine against Emerging Flaviviruses

    Emerging flaviviruses are causative agents of severe and life-threatening diseases, against which no approved therapies are available. Among the nucleoside analogues, which represent a promising group of potentially therapeutic compounds, fluorine-substituted nucleosides are characterized by unique structural and functional properties.

    Luděk Eyer, Pavel Svoboda, Jan Balvan, Tomáš Vičar, Matina Raudenská, Michal Štefánik, Jan Haviernik, Ivana Huvarová, Petra Straková, Ivo Rudolf, Zdeněk Hubálek, Katherine Seley-Radtke, Erik de Clercq, Daniel Růžek
  • Mutations in <em>fbiD</em> (<em>Rv2983</em>) as a Novel Determinant of Resistance to Pretomanid and Delamanid in <span class="named-content genus-species" id="named-content-1">Mycobacterium tuberculosis</span>
    Editor's Pick Mechanisms of Resistance
    Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis

    The nitroimidazole prodrugs delamanid and pretomanid comprise one of only two new antimicrobial classes approved to treat tuberculosis (TB) in 50 years. Prior in vitro studies suggest a relatively low barrier to nitroimidazole resistance in Mycobacterium tuberculosis, but clinical evidence is limited to date. We selected pretomanid-resistant...

    Dalin Rifat, Si-Yang Li, Thomas Ioerger, Keshav Shah, Jean-Philippe Lanoix, Jin Lee, Ghader Bashiri, James Sacchettini, Eric Nuermberger
  • Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus
    Antiviral Agents
    Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus

    Human influenza A and B viruses are highly contagious and cause similar illnesses and seasonal epidemics. Currently available antiviral drugs have limited efficacy in humans with compromised immune systems; therefore, alternative strategies for protection are needed. Here, we investigated whether monoclonal antibodies (MAbs) targeting hemagglutinin (HA) and/or neuraminidase (NA) proteins would protect immunosuppressed mice from severe...

    Bindumadhav M. Marathe, Guha Asthagiri Arunkumar, Peter Vogel, Philippe Noriel Q. Pascua, Jeremy Jones, Richard J. Webby, Florian Krammer, Elena A. Govorkova
  • Open Access
    AR-12 Exhibits Direct and Host-Targeted Antibacterial Activity toward <em>Mycobacterium abscessus</em>
    Susceptibility
    AR-12 Exhibits Direct and Host-Targeted Antibacterial Activity toward Mycobacterium abscessus

    Therapeutic options for Mycobacterium abscessus infections are extremely limited. New or repurposed drugs are needed. The anti-M. abscessus activity of AR-12 (OSU-03012), reported to express broad-spectrum antimicrobial effects, was investigated in vitro and in vivo. Antimicrobial...

    Shaoyan Zhang, Yuzhen Zou, Qi Guo, Jianhui Chen, Liyun Xu, Xiaoyu Wan, Zhemin Zhang, Bing Li, Haiqing Chu
  • Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of <em>Mycobacterium avium</em> Infection
    Experimental Therapeutics
    Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection

    Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recommended treatment; therefore, we aimed to study its in vivo activity in an aerosol mouse model of...

    Jean-Philippe Lanoix, Cédric Joseph, François Peltier, Sandrine Castelain, Claire Andréjak
  • Identification of Antibiotics That Diminish Disease in a Murine Model of Enterohemorrhagic <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Infection
    Experimental Therapeutics
    Identification of Antibiotics That Diminish Disease in a Murine Model of Enterohemorrhagic Escherichia coli Infection

    Infections with enterohemorrhagic Escherichia coli (EHEC) cause disease ranging from mild diarrhea to hemolytic-uremic syndrome (HUS) and are the most common cause of renal failure in children in high-income countries. The severity of the disease derives from the release of Shiga toxins (Stx). The use of antibiotics to treat EHEC infections is generally avoided, as it...

    Sabrina Mühlen, Isabell Ramming, Marina C. Pils, Martin Koeppel, Jana Glaser, John Leong, Antje Flieger, Bärbel Stecher, Petra Dersch
  • Open Access
    Mechanistic Modeling of <span class="named-content genus-species" id="named-content-1">Mycobacterium tuberculosis</span> Infection in Murine Models for Drug and Vaccine Efficacy Studies
    Editor's Pick Experimental Therapeutics
    Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies

    Tuberculosis (TB) drug, regimen, and vaccine development rely heavily on preclinical animal experiments, and quantification of bacterial and immune response dynamics is essential for understanding drug and vaccine efficacy. A mechanism-based model was built to describe Mycobacterium tuberculosis H37Rv infection over time in BALB/c and athymic nude mice, which...

    Nan Zhang, Natasha Strydom, Sandeep Tyagi, Heena Soni, Rokeya Tasneen, Eric L. Nuermberger, Rada M. Savic
  • Open Access
    Rifabutin Is Active against <span class="named-content genus-species" id="named-content-1">Mycobacterium abscessus</span> in Mice
    Editor's Pick Experimental Therapeutics
    Rifabutin Is Active against Mycobacterium abscessus in Mice

    There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus. Here, we...

    Thomas Dick, Sung Jae Shin, Won-Jung Koh, Véronique Dartois, Martin Gengenbacher
  • Open Access
    Advancing the Therapeutic Potential of Indoleamides for Tuberculosis
    Experimental Therapeutics
    Advancing the Therapeutic Potential of Indoleamides for Tuberculosis

    Indole-2-carboxamide derivatives are inhibitors of MmpL3, the cell wall-associated mycolic acid transporter of Mycobacterium tuberculosis. In the present study, we characterized indoleamide effects on bacterial cell morphology and reevaluated pharmacokinetics and in vivo efficacy using an optimized oral formulation.

    Shichun Lun, Rokeya Tasneen, Tridib Chaira, Jozef Stec, Oluseye K. Onajole, Tian J. Yang, Christopher B. Cooper, Khisi Mdluli, Paul J. Converse, Eric L. Nuermberger, V. Samuel Raj, Alan Kozikowski, William R. Bishai
  • Pharmacokinetic Data Are Predictive of <em>In Vivo</em> Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant <em>Neisseria gonorrhoeae</em> Strains in the Gonorrhea Mouse Model
    Pharmacology
    Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model

    There is a pressing need for drug development for gonorrhea. Here we describe a pharmacokinetic (PK)/pharmacodynamic (PD) analysis of extended-spectrum cephalosporins (ESC) against drug-susceptible and drug-resistant gonococcal strains in a murine genital tract infection model.

    Kristie L. Connolly, Ann E. Eakin, Carolina Gomez, Blaire L. Osborn, Magnus Unemo, Ann E. Jerse

Pages

  • Next
  • 1
  • 2
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596